France · Source-listed medicine information
France / CIS 65915750
BCG MAJORELLE 100 mg, poudre et solvant pour suspension intravésicale
poudre et solvant pour suspension · intravésicale
Source data retrieved: 2026-09-17. Clinical review is not yet available.
Product identity
At a glance
- Authorisation holder
- LABORATOIRES MAJORELLE
- Authorisation status
- Autorisation active
- Market status
- Commercialisée
- Country
- France
- Source reference
- CIS 65915750
Reported market status does not confirm current pharmacy stock.
From the official composition record
Ingredients & strength
Source entries are shown individually. An active substance (SA) and its reference moiety (FT) may describe the same ingredient; do not add their strengths together.
| Ingredient | Strength / reference | Source role |
|---|---|---|
| BCG (BACILLE DE CALMETTE-GUÉRIN) VIVANT, ATTÉNUÉ - SOUCHE BRÉSILIENNE MOREAU poudre | 3,0 x 10^8 à 12,0 x 10^8 unités viablesun flacon ou une ampoule de 100 mg après reconstitutio | SAGroup 1 |
Pack references
Presentations (1)
CIP13 3400930297612
Présentation active · Déclaration de commercialisationFrom the French medicines authority
Official documents
The official product entry provides access to the patient leaflet and professional product information when available. Documents are in French and availability varies by medicine.
Open the official product entryBDPM · CIS 65915750 · Opens in a new tabCheck the medicine name, strength and form against your pack. The authority’s current documents may be newer than the catalogue snapshot shown here.
Where this information comes from
Sources & dates
Base de données publique des médicaments (BDPM), France. Retrieval dates record when we obtained the source files; they are not clinical review dates or a guarantee of current stock.
| Source file | Retrieved | Source file modified |
|---|---|---|
| fr_products.txt | Not supplied | |
| fr_composition.txt | Not supplied | |
| fr_packs.txt | Not supplied |
Directory source checks cover the factual catalogue record.Molindra clinical guidance has not yet been reviewed or published for this medicine.
Our sources and review process →